Cloning Concerns
By Richard Hayes,
Washington Post
| 11. 24. 2007
As the Nov. 21 front-page article "Advance May End Stem Cell Debate" implied, religious conservatives are not the only ones concerned about the use of human cloning for stem cell research. Many liberals, progressives and supporters of women's health and reproductive rights are uneasy for reasons of their own.
Cloning-based stem cell therapies have been projected to cost upward of $100,000 per treatment, raising questions of health equity and access.
Cloning for stem cell research opens the door to reproductive cloning and to high-tech eugenic and "designer baby" applications. And millions of women's eggs would be needed each year to supply the proposed cloning-based "personalized medicine" industry.
With this week's stem cell breakthroughs, the embryo wars may be behind us. Liberals are now in a position to take the lead in drawing attention to the social justice and human rights concerns that the new human genetic technologies raise.
RICHARD HAYES
Executive Director
Center for Genetics and Society
Oakland, Calif.
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
